FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893850807> ?p ?o ?g. }

• W2893850807 endingPage "175883591879758" @default.
• W2893850807 startingPage "175883591879758" @default.
• W2893850807 abstract "Brain metastases (BM) are common in advanced non-small cell lung cancer (NSCLC), and the prognosis is poor with few therapeutic options. This study evaluated the efficacy of three epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in preventing and treating BM in patients with EGFR mutation-positive advanced NSCLC.Patients with EGFR mutation-positive advanced NSCLC who visited a tertiary referral center from 1 December 2013 to 30 November 2017 were analyzed retrospectively. They received gefitinib, erlotinib, or afatinib until disease progression, death, or intolerable adverse events. The cumulative incidence of subsequent BM of initial non-BM patients, progression-free survival (PFS), and overall survival (OS) of the BM and non-BM patients were estimated and compared using the Kaplan-Meier and log-rank tests.306 NSCLC patients were enrolled, with 116, 75, and 115 receiving first-line gefitinib, erlotinib, and afatinib, respectively. The afatinib group had a better PFS [12.7 versus 9.8 months; hazard ratio (HR) 0.59, p = 0.001] and OS (39.1 versus 22.0 months; HR 0.64, p = 0.035) than the gefitinib group. Afatinib tended to provide better BM prevention than gefitinib (BM cumulative incidence, HR 0.49; 95% confidence interval 0.34-0.71, p < 0.001) according to a Cox model adjusted for possible confounders. Patients with initial BM had a shorter PFS (p < 0.001) and OS (p = 0.015) than those without initial BM. Among the former, there were no differences in median PFS (p = 0.34) and median OS (p = 0.46) in the three EGFR-TKI groups.Our data suggested that, compared with gefitinib, afatinib provided better benefits significantly in terms of PFS and OS. Both had the same effectiveness in preventing subsequent BM." @default.
• W2893850807 created "2018-10-05" @default.
• W2893850807 creator A5028941663 @default.
• W2893850807 creator A5036098587 @default.
• W2893850807 creator A5038414832 @default.
• W2893850807 creator A5041139618 @default.
• W2893850807 creator A5046508238 @default.
• W2893850807 creator A5050173955 @default.
• W2893850807 creator A5059929672 @default.
• W2893850807 creator A5060246976 @default.
• W2893850807 creator A5074389690 @default.
• W2893850807 date "2018-01-01" @default.
• W2893850807 modified "2023-10-17" @default.
• W2893850807 title "Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer" @default.
• W2893850807 cites W1836211457 @default.
• W2893850807 cites W1966683718 @default.
• W2893850807 cites W1968061903 @default.
• W2893850807 cites W1980011909 @default.
• W2893850807 cites W1999896690 @default.
• W2893850807 cites W2000470201 @default.
• W2893850807 cites W2011633764 @default.
• W2893850807 cites W2025208846 @default.
• W2893850807 cites W2061136476 @default.
• W2893850807 cites W2063990035 @default.
• W2893850807 cites W2070582403 @default.
• W2893850807 cites W2075023076 @default.
• W2893850807 cites W2109950864 @default.
• W2893850807 cites W2124569973 @default.
• W2893850807 cites W2126799977 @default.
• W2893850807 cites W2132870547 @default.
• W2893850807 cites W2136876211 @default.
• W2893850807 cites W2146404049 @default.
• W2893850807 cites W2151204647 @default.
• W2893850807 cites W2155894313 @default.
• W2893850807 cites W2157823581 @default.
• W2893850807 cites W2218718059 @default.
• W2893850807 cites W2268267848 @default.
• W2893850807 cites W2339311613 @default.
• W2893850807 cites W2418806722 @default.
• W2893850807 cites W2487033212 @default.
• W2893850807 cites W2521375161 @default.
• W2893850807 cites W2560641280 @default.
• W2893850807 cites W2589049928 @default.
• W2893850807 cites W2604383642 @default.
• W2893850807 cites W2609708249 @default.
• W2893850807 cites W2738531764 @default.
• W2893850807 cites W2748695779 @default.
• W2893850807 cites W2765831845 @default.
• W2893850807 cites W2785986820 @default.
• W2893850807 cites W2792898551 @default.
• W2893850807 cites W2964623804 @default.
• W2893850807 doi "https://doi.org/10.1177/1758835918797589" @default.
• W2893850807 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6156208" @default.
• W2893850807 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30263066" @default.
• W2893850807 hasPublicationYear "2018" @default.
• W2893850807 type Work @default.
• W2893850807 sameAs 2893850807 @default.
• W2893850807 citedByCount "40" @default.
• W2893850807 countsByYear W28938508072019 @default.
• W2893850807 countsByYear W28938508072020 @default.
• W2893850807 countsByYear W28938508072021 @default.
• W2893850807 countsByYear W28938508072022 @default.
• W2893850807 countsByYear W28938508072023 @default.
• W2893850807 crossrefType "journal-article" @default.
• W2893850807 hasAuthorship W2893850807A5028941663 @default.
• W2893850807 hasAuthorship W2893850807A5036098587 @default.
• W2893850807 hasAuthorship W2893850807A5038414832 @default.
• W2893850807 hasAuthorship W2893850807A5041139618 @default.
• W2893850807 hasAuthorship W2893850807A5046508238 @default.
• W2893850807 hasAuthorship W2893850807A5050173955 @default.
• W2893850807 hasAuthorship W2893850807A5059929672 @default.
• W2893850807 hasAuthorship W2893850807A5060246976 @default.
• W2893850807 hasAuthorship W2893850807A5074389690 @default.
• W2893850807 hasBestOaLocation W28938508071 @default.
• W2893850807 hasConcept C121608353 @default.
• W2893850807 hasConcept C126322002 @default.
• W2893850807 hasConcept C143998085 @default.
• W2893850807 hasConcept C207103383 @default.
• W2893850807 hasConcept C2776256026 @default.
• W2893850807 hasConcept C2776694085 @default.
• W2893850807 hasConcept C2777930144 @default.
• W2893850807 hasConcept C2778087573 @default.
• W2893850807 hasConcept C2779438470 @default.
• W2893850807 hasConcept C2780580887 @default.
• W2893850807 hasConcept C2780586478 @default.
• W2893850807 hasConcept C2780739268 @default.
• W2893850807 hasConcept C44249647 @default.
• W2893850807 hasConcept C71924100 @default.
• W2893850807 hasConcept C72563966 @default.
• W2893850807 hasConcept C88879693 @default.
• W2893850807 hasConceptScore W2893850807C121608353 @default.
• W2893850807 hasConceptScore W2893850807C126322002 @default.
• W2893850807 hasConceptScore W2893850807C143998085 @default.
• W2893850807 hasConceptScore W2893850807C207103383 @default.
• W2893850807 hasConceptScore W2893850807C2776256026 @default.
• W2893850807 hasConceptScore W2893850807C2776694085 @default.
• W2893850807 hasConceptScore W2893850807C2777930144 @default.
• W2893850807 hasConceptScore W2893850807C2778087573 @default.

• next